Federal
Register Notices > Notice of
Application 2006 >
MGI Pharma
FR Doc E6-12172 [Federal Register: July 31, 2006 (Volume 71, Number 146)]
[Notices] [Page 43211] From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr31jy06-90]
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to section 1301.33(a) of Title 21 of the Code of Federal Regulations
(CFR), this is notice that on October 28, 2005, MGI Pharma, 6611 Tributary
Street, Baltimore, Maryland 21224, made application to the Drug Enforcement
Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041),
a basic class of controlled substance listed in Schedules II.
The company plans to manufacture a cocaine derivative to be used in domestic
and foreign clinical research studies. Any other such applicant and any person
who is presently registered with DEA to manufacture such a substance may file
comments or objections to the issuance of the proposed registration pursuant to 21
CFR 1301.33(a).
Any such written comments or objections being sent via regular mail should be
addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement Administration, Washington, DC 20537,
Attention: DEA Federal Register Representative/ODL; or any being sent via
express mail should be sent to DEA Headquarters, Attention: DEA Federal Register
Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301;
and must be filed no later than September 29, 2006.
Dated: July 25, 2006.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E6-12172 Filed 7-28-06; 8:45 am]
BILLING CODE 4410-09-P
NOTICE: This is an
unofficial version. An official version of these publications may be obtained
directly from the Government Printing Office (GPO).
|